{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-341293","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2026-08-10T11:57:19+00:00","discovered_at":"2026-08-10T12:00:04.355692+00:00","generated_at":"2026-08-10T12:00:11.410483+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Silence Therapeutics reports positive Phase 2 SANRECO topline: 88% vs 19% responder rate","bullets":["Primary endpoint met: 88% clinical responders on divesiran vs 19% placebo (p<0.0001); placebo-adjusted 69%.","Both dose groups strong: 93.8% response at Q6W, 81.3% at Q12W in 48 phlebotomy-dependent PV patients.","Phlebotomy rate cut to 0.2 vs 2.1 per patient (p<0.0001); hematocrit control and MPN-SAF TSS improved.","Well tolerated, no new safety findings; two grade 1 anemia cases. Phase 3 Q12W vs placebo expected 1H'27."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-341293","json":"https://secwatch.observer/filing/0001193125-26-341293.json","markdown":"https://secwatch.observer/filing/0001193125-26-341293.md","text":"https://secwatch.observer/filing/0001193125-26-341293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/0001193125-26-341293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/d12947d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T12:00:11.410483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}